About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Pharmacogenetics Associated With IV Ketamine | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT04695405

Pharmacogenetics Associated With IV Ketamine

The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from tr...

Lead sponsor: Brain and Cognition Discovery Foundation•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Brain and Cognition Discovery Foundation

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Must have received IV ketamine previously to treat Treatment-Resistant Depression
•2. Between the ages of 18-65 years old.
•3. Clinical diagnosis of MDD
•4. Individuals may have had comorbid psychiatric conditions (e.g., anxiety), but the comorbid psychiatric condition cannot be the primary clinical concern.
•5. Ability to provide informed consent

Exclusion Criteria

•1. Individuals who meet DSM 5 criteria for a substance use and/or alcohol use disorder in the past 3 months.
•2. Individuals who are currently experiencing psychotic symptoms as part of an MDE (mood congruent/mood incongruent).
•3. Individuals who are unable to consent to the procedure.
•4. Individuals who are unable to adhere to the protocol in its totality

Related studies

Transcranial Ultrasonic Stimulation in Treatment-resistant Depression : an Open-label Pilot Trial

NCT06085950 · Treatment Resistant Depression

RECRUITINGPhase 3

Ketamine Augmentation of ECT in Treatment-Resistant Depression

NCT07088380 · Major Depressive Disorder, Treatment Resistant Depression

Maintenance rTMS for Depression (Maitr-De)

NCT06938841 · Major Depressive Disorder, Treatment Resistant Depression

RECRUITINGPhase 1

Psilocybin for Treatment-Resistant Depression in Autism

NCT06731621 · Treatment Resistant Depression, Autism Spectrum Disorder

Characterizing Dopamine Receptor Binding in Treatment Resistant Depression

NCT03537794 · Treatment Resistant Depression

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 18, 2021Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment85

Start dateJan 2021

Last updatedAug 18, 2021

Condition

Treatment Resistant Depression

Locations shown

Canadian Rapid Treatment Centre of Excellence

Mississauga, Ontario

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 18, 2021Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions